Serum, Plasma, DNA and Tissue Bank in Chronic Obstructive Pulmonary Disease and Lung Cancer
NCT ID: NCT00858520
Last Updated: 2013-09-04
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
2000 participants
OBSERVATIONAL
2007-10-31
2019-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The objective is to study candidate gene pathways in COPD and or lung cancer and to associate them with the clinical characteristics and phenotypes of COPD/emphysema and lung cancer.
In subgroups of well characterised patients, other biological materials are also collected (lung tissue biopsies, peripheral blood mononuclear cells).
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
All subjects with a diagnosis of lung cancer are also collected (irrespective of age and smoking behavior).
In addition the investigators collect:
* specific questionnaires (MRC, CCQ and smoking history)
* medical and professional history
* complete pulmonary function (spirometry, bodyplethysmography and diffusing capacity)
* serum, plasma and DNA samples.
In specific subgroups the investigators also collect:
* Peripheral blood mononuclear cells
* Lung tissue - if available - from a surgical procedure (lung transplantation or lobectomy)
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Smoking controls
Smokers without lung cancer and without COPD
No interventions assigned to this group
COPD patients
Smokers with COPD but without lung cancer
No interventions assigned to this group
Lung cancer patients
smokers - never smokers with lung cancer
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Complete pulmonary function on day of visit
* Chest CT-scan within one year of enrollment
* 4 weeks from exacerbation
* new diagnosis of proven lung cancer
* chest CT scan within 2 months of enrollment
* Complete pulmonary function
Exclusion Criteria
* Younger than 50 year
* Other pulmonary diseases interfering with CT or pulmonary function
* Asthma
* not able to perform pulmonary function
* Absence of histological diagnosis of lung cancer
25 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
KU Leuven
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Marc Decramer
Prof.Dr.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Wim Janssens, MD. PhD.
Role: PRINCIPAL_INVESTIGATOR
KU Leuven
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Katholieke Universiteit Leuven
Leuven, Flanders, Belgium
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Wim Janssens, Prof
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
S50623
Identifier Type: -
Identifier Source: secondary_id
B32220072389
Identifier Type: -
Identifier Source: org_study_id